Amber Therapeutics Raises $100M to Revolutionize Neuromodulation Therapies: Unveiling Amber UI for Mixed Urinary Incontinence

Amber Therapeutics is excited to announce a significant funding milestone, successfully raising $100 million to accelerate the development of its pioneering neuromodulation therapies. Founded in 2021, Amber Therapeutics is committed to delivering transformative medical solutions in areas of unmet clinical need. The company has quickly assembled a talented and multidisciplinary team that blends extensive experience in medical device development with a vision centered around innovation and patient care. The newly secured capital will play a pivotal role in advancing Amber UI, the company’s first therapy designed to restore normal physiological function in women suffering from mixed urinary incontinence, a condition that affects millions worldwide. Current treatment options for this complex condition are limited, and Amber UI aims to fill this critical gap by providing an innovative, effective solution that enhances quality of life for patients. This funding marks a significant endorsement of Amber Therapeutics' mission and progress, as it moves closer to clinical trials and commercialization of Amber UI. The funds will also facilitate expanded research and development efforts, enabling the company to explore additional therapeutic applications using its neuromodulation technology. As we embark on this exciting journey, we are immensely grateful to our investors for their belief in our vision and are determined to pave the way toward better health outcomes for women facing mixed urinary incontinence and beyond.